MedTrace Logo

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

NCT04470726 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-12-27

No results posted yet for this study

Summary

To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.

Conditions

  • Superficial Basal Cell Carcinoma
  • Nodular Basal Cell Carcinoma
  • Nonmelanoma Skin Cancers

Interventions

DRUG

AIV001

Intradermal/intratumoral

DRUG

AIV001 suspension

AIV001 is administered as a aqueous suspension by an intradermal/intratumoral injection

Sponsors & Collaborators

  • AiViva BioPharma, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-18
Primary Completion
2023-06-20
Completion
2023-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470726 on ClinicalTrials.gov